Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Allogene Therapeutics Inc (NQ: ALLO ) 2.610 +0.020 (+0.77%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Allogene Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 Next > A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics August 08, 2024 Via Benzinga Allogene Therapeutics Announces Participation in Upcoming Investor Conferences August 08, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire 7 Biotech Stocks to Buy for Their Game-Changing Potential August 08, 2024 Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. Via InvestorPlace Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update August 07, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Analyst Ratings For Allogene Therapeutics May 31, 2024 Via Benzinga Breaking Down Allogene Therapeutics: 5 Analysts Share Their Views May 15, 2024 Via Benzinga Recap: Allogene Therapeutics Q4 Earnings March 14, 2024 Via Benzinga Allogene Therapeutics Earnings Preview March 13, 2024 Via Benzinga Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update July 31, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges July 19, 2024 CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune... Via Benzinga Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL) July 01, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse June 20, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names May 28, 2024 Penny stocks to buy carry a great deal of risk. However, there are a few that look interesting after due diligence. Via InvestorPlace Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit May 23, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 21, 2024 Via Benzinga Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket May 21, 2024 Via Benzinga Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket May 15, 2024 Via Benzinga DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session May 15, 2024 Via Benzinga ALLO Stock Earnings: Allogene Therapeutics Beats EPS, Beats Revenue for Q1 2024 May 13, 2024 ALLO stock results show that Allogene Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock May 13, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update May 13, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update May 06, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Pre-Market Session May 06, 2024 Via Benzinga Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma April 26, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation April 18, 2024 Via Benzinga Topics ETFs 3 Meme Stocks to Sell and Replace With Meme Coins April 11, 2024 For investors who want to avoid losses, sell or avoid certain meme stocks that are on the radar for potential sell-offs. Via InvestorPlace Allogene Therapeutics Announces Q2 Investor Conference Participation April 09, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire ALLO Stock Earnings: Allogene Therapeutics Misses EPS, Beats Revenue for Q4 2023 March 14, 2024 ALLO stock results show that Allogene Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. Via InvestorPlace Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update March 14, 2024 From Allogene Therapeutics, Inc. Via GlobeNewswire Earnings Scheduled For March 14, 2024 March 14, 2024 Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.